RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00051909.xml
PDF herunterladen
Angewandte Nuklearmedizin 2025; 48(03): 159-165
DOI: 10.1055/a-2385-3662
DOI: 10.1055/a-2385-3662
PET/CT
Übersicht
PSMA PET/CT zum Staging und Restaging des Prostatakarzinoms
PSMA PET/CT for staging and restaging of prostate cancer
Zusammenfassung
Das Prostatakarzinom ist die häufigste Krebserkrankung bei Männern weltweit. Eine präzise Bildgebung ist entscheidend für das Staging, die Therapieplanung und das Restaging der Erkrankung, insbesondere bei fortgeschrittenen Stadien oder Rezidiven. Die PSMA PET hat sich als präzise Methode zur Beurteilung des Tumorstadiums etabliert, indem sie das Prostata-spezifische Membranantigen (PSMA) als Zielmolekül nutzt, welches in ca. 85% auf Prostatakarzinomzellen überexprimiert wird. Im Vergleich zu konventionellen Bildgebungsverfahren wie der Computertomographie (CT), Magnetresonanztomographie (MRT) und Skelettszintigrafie bietet die PSMA PET/CT eine höhere Sensitivität und Präzision bei der Detektion von Metastasen. Die PSMA PET kann bei Vorliegen eines Prostatakarzinoms sowohl für das initiale Staging im high-risk Stadium als auch in der Situation des biochemischen Rezidivs genutzt werden, findet aber auch Einsatz im Restaging des fortgeschrittenen, metastasierten oder progredienten Prostatakarzinoms sowie vor Durchführung der PSMA-gerichteten Radioligandentherapie zur Evaluation einer ausreichenden PSMA-Expression. Insgesamt stellt die PSMA PET/CT eine revolutionäre Weiterentwicklung in der Bildgebung und Therapie des Prostatakarzinoms dar.
Abstract
Prostate cancer is the most common cancer in men worldwide. Accurate imaging is critical for staging, treatment planning and restaging of the disease, especially in advanced or recurrent disease. PSMA PET has established itself as an accurate method of staging prostate cancer using prostate-specific membrane antigen (PSMA) as a target molecule, which is over-expressed on prostate cancer cells in approximately 85% of cases. Compared to conventional imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI) and skeletal scintigraphy, PSMA PET/CT offers greater sensitivity and accuracy in detecting metastases.PSMA PET/CT can be used for initial staging of high-risk prostate cancer and for biochemical recurrence, as well as for restaging of advanced, metastatic or progressive prostate cancer and prior to PSMA-directed radioligand therapy for evaluating a sufficient PSMA expression. Overall, PSMA PET/CT represents a revolutionary advance in the imaging and treatment of prostate cancer.
Publikationsverlauf
Artikel online veröffentlicht:
02. September 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literaturverzeichnis
- 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Prostatakarzinom, Langversion 7.0, 2024, AWMF-Registernummer:043–022OL. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatatkarzinom/Version_7/LL_Prostatakarzinom_Langversion_7.0.pdf
- 2 Gesellschaft, R.K. Epidemiologischer Krebsregister in Deutschland. Prostatakarzinom 2020.. Zugriff am 27. Juli 2024 unter: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Prostatakrebs/prostatakrebs_node.html
- 3 Siegel DA, O'Neil ME, Richards TB. et al. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001–2017. MMWR Morb Mortal Wkly Rep 2020; 69: 1473-1480
- 4 Farolfi A, Calderoni L, Mattana F. et al. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. J Nucl Med 2021; 62: 596-604
- 5 Unterrainer LM, Calais J, and Bander NH. Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annu Rev Med 2024; 75: 49-66
- 6 Attenberger U, Ritter M, and Wenz F. MR-und PET-Bildgebung der Prostata. Berlin, Heidelberg: Springer; 2017
- 7 Conway RE, Petrovic N, Li Z. et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26: 5310-5324
- 8 Eiber M, Weirich G, Holzapfel K. et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016; 70: 829-836
- 9 Maurer T, Gschwend JE, Rauscher I. et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016; 195: 1436-1443
- 10 Hofman MS, Hicks RJ, Maurer T. et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018; 38: 200-217
- 11 Fendler WP, Calais J, Eiber M. et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 2019; 5: 856-863
- 12 Parsi M, Desai MH, Desai D. et al. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol 2021; 38: 89
- 13 Horoszewicz JS, Kawinski E, and Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-935
- 14 Manyak MJ, Hinkle GH, Olsen JO. et al. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54: 1058-1063
- 15 Kuppermann D, Calais J, Marks LS. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. J Urol 2022; 207: 769-778
- 16 Bander NH, Trabulsi EJ, Kostakoglu L. et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721
- 17 Afshar-Oromieh A, Haberkorn U, Eder M. et al. 68Ga. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086
- 18 Kuten J, Fahoum I, Savin Z. et al. Head-to-Head Comparison of (68)Ga-PSMA-11 with (18)F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med 2020; 61: 527-532
- 19 Hope TA, Eiber M, Armstrong WR. et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol 2021; 7: 1635-1642
- 20 Hofman MS, Lawrentschuk N, Francis RJ. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-1216
- 21 Pyka T, Okamoto S, Dahlbender M. et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-2121
- 22 Bräuer A, Rahbar K, Konnert J. et al. Diagnostic value of additional (68)Ga-PSMA-PET before (223)Ra-dichloride therapy in patients with metastatic prostate carcinoma. Nuklearmedizin 2017; 56: 14-22
- 23 Lowrance WT, Breau RH, Chou R. et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol 2021; 205: 22-29
- 24 Lowrance WT, Breau RH, Chou R. et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol 2021; 205: 14-21
- 25 Mottet N, van den Bergh RCN, Briers E. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021; 79: 243-262
- 26 Parker C, Castro E, Fizazi K. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1119-1134
- 27 Schaeffer EM, Srinivas S, Adra N. et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw 2022; 20: 1288-1298
- 28 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Prostatakarzinom, Langversion 8.01, 2025, AWMF-Registernummer:043–022OL. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatatkarzinom/Version_8/LL_Prostatakarzinom_Langversion_8.01_Konsultationsfassung.pdf
- 29 Malaspina S, Anttinen M, Taimen P. et al. Prospective comparison of (18)F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 2021; 48: 2951-2959
- 30 Pianou NK, Stavrou PZ, Vlontzou E. et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT. Hell J Nucl Med 2019; 22: 6-9
- 31 Wilson ZJ, Xu G, Tewari SO. et al. Comparison of PSMA-based (18)F-DCFPyL PET/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer. Am J Nucl Med Mol Imaging 2023; 13: 1-10
- 32 Nikitas J, Gafita A, Benz MR. et al. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep 2024; 14: 24411
- 33 Emmett L, Papa N, Buteau J. et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med 2022; 63: 1644-1650
- 34 Emmett L, Buteau J, Papa N. et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol 2021; 80: 682-689
- 35 Amin A, Blazevski A, Thompson J. et al. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int 2020; 125: 515-524
- 36 Wang C, Dong Q, Liu X. et al. Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following (18)F-PSMA-1007 PET/CT based on a diagnostic model: a single-centre, single-arm, open-label study. BMJ Open 2023; 13: e073983
- 37 Zhang LL, Li WC, Xu Z. et al. (68)Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging 2021; 48: 483-492
- 38 Baas DHJ, Schilham M, Hermsen R. et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostatic Dis 2022; 25: 65-70
- 39 Dekalo S, Kuten J, Mintz I. et al. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostatic Dis 2021; 24: 910-916
- 40 Cytawa W, Seitz AK, Kircher S. et al. (68)Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging 2020; 47: 168-177
- 41 James ND, de Bono JS, Spears MR. et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377: 338-351
- 42 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373: 737-46
- 43 Simon NI, Parker C, Hope TA. et al. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. Am Soc Clin Oncol Educ Book 2022; 42: 1-8
- 44 Cookson MS, Aus G, Burnett AL. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-545
- 45 Holzgreve A, Armstrong WR, Clark KJ. et al. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Network Open 2025; 8: e2452971-e2452971
- 46 Morigi JJ, Stricker PD, van Leeuwen PJ. et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med 2015; 56: 1185-1190
- 47 Bagguley D, Ong S, Buteau JP. et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol 2021; 17: 2225-2241
- 48 von Eyben R, Hoffmann MA, Soydal C. et al. Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer. Biomedicines 2023; 11: 2333
- 49 Sawicki LM, Kirchner J, Buddensieck C. et al. Prospective comparison of whole-body MRI and (68)Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2019; 46: 1542-1550
- 50 Morawitz J, Kirchner J, Lakes J. et al. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur J Radiol 2021; 136: 109556
- 51 Christensen MT, Jochumsen MR, Klingenberg S. et al. Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT. Diagnostics (Basel) 2022; 12: 195
- 52 Wetterauer C, Seifert H, Chirindel A. et al. Die Rolle der PSMA-PET-CT in der Diagnostik und Therapie des Prostatakarzinoms. Urologie in der Praxis 2020; 22: 100-104
- 53 Alongi P, Laudicella R, Lanzafame H. et al. PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. Cancers (Basel) 2022; 14: 1770
- 54 Zamani-Siahkali N, Mirshahvalad SA, Farbod A. et al. SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases. Semin Nucl Med 2024; 54: 356-370
- 55 Grubmüller B, Rasul S, Baltzer P. et al. Response assessment using [(68) Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate 2020; 80: 74-82
- 56 Seifert R, Emmett L, Rowe SP. et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023; 83: 405-412
- 57 Werner RA, Hartrampf PE, Fendler WP. et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023; 84: 491-502
- 58 Karpinski MJ, Hüsing J, Claassen K. et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol 2024; 25: 1188-1201
- 59 Dullea A, O'Sullivan L, O'Brien KK. et al. Diagnostic Accuracy of (18)F-Prostate Specific Membrane Antigen (PSMA) PET/CT Radiotracers in Staging and Restaging of Patients With High-Risk Prostate Cancer or Biochemical Recurrence: An Overview of Reviews. Semin Nucl Med 2024; 6: 57
- 60 Fendler WP, Eiber M, Beheshti M. et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 2023; 50: 1466-1486
- 61 Fanti S, Goffin K, Hadaschik BA. et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 2021; 48: 469-476
- 62 Kratochwil C, Fendler WP, Eiber M. et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019; 46: 2536-2544
- 63 Fendler WP, Karpinski MJ, Hüsing J. et al. Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer. Journal of Clinical Oncology 2024; 42: 5016-5016
- 64 Wang Q, Ketteler S, Bagheri S. et al. Diagnostic efficacy of [99mTc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis. BMC Cancer 2024; 24: 982
- 65 Yunusa GH, Kaoje AU, Orunmuyi AT. et al. Comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer: a protocol for systematic review and meta-analysis. Egyptian Journal of Radiology and Nuclear Medicine 2021; 52: 179
- 66 Gafita A, Rauscher I, Weber M. et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med 2022; 63: 1651-1658
- 67 Bundesvereinigung, K. BESCHLUSS des Bewertungsausschusses nach § 87 Abs. 1 Satz 1 SGB V in seiner 676. Sitzung (schriftliche Beschlussfassung). 2023. Zugriff am 13. August 2024 unter: https://www.kbv.de/media/sp/EBM_2023–10–01_BA_676_BeeG_Pluvicto.pdf
- 68 Bundesausschuss, G. Ambulante spezialfachärztliche Versorgung um neue Diagnostik und digitale Anwendungen erweitert. 2022.. Zugriff am 23. April 2025 unter: https://www.g-ba.de/service/fachnews/23/
- 69 Rizzo A, Morbelli S, Albano D. et al. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 2024; 51: 3753-3764
- 70 Bauckneht M, Miceli A, Signori A. et al. Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study. Eur Radiol 2023; 33: 3343-3353
- 71 Poulsen MH, Rasmussen J, Edenbrandt L. et al. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int 2016; 117: 748-753
- 72 Seifert R, Rasul S, Seitzer K. et al. A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes. Radiology 2023; 307: e222010